Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Islatravir on Methadone Pharmacokinetics
NCT04568603Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of islatravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose of R-Methadone at Day 2 and Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose of S-Methadone at Day 2. Started Oct 2020; status: completed.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04568603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568603.